Association of the CYP2B6 c.516G>T polymorphism with high blood propofol concentrations in women from Northern Greece

Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 2, 2014, Pages 215-218

  Mastrogianni, Orthodoxia ^a   Gbandi, Emma ^a   Orphanidis, Amvrosios ^a   Raikos, Nikolaos ^a   Goutziomitrou, Evangelia ^a   Kolibianakis, Efstratios M ^a   Tarlatzis, Basil C ^a   Goulas, Antonis ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Blood propofol; CYP2B6; GC MS; Gene polymorphism

Indexed keywords

CYTOCHROME P450 2B6; PROPOFOL; CYP2B6 PROTEIN, HUMAN; INTRAVENOUS ANESTHETIC AGENT;

ADULT; AGE; ALLELE; ARTICLE; BODY HEIGHT; BODY WEIGHT; CYP2B6 GENE; DRUG BLOOD LEVEL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GREECE; HUMAN; MASS FRAGMENTOGRAPHY; OOCYTE RETRIEVAL; RANK SUM TEST; SINGLE DRUG DOSE; SMOKING; BIOTRANSFORMATION; BLOOD; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PHENOTYPE; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANESTHETICS, INTRAVENOUS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2B6; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GENOTYPE; GREECE; HUMANS; INJECTIONS, INTRAVENOUS; OOCYTE RETRIEVAL; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPOFOL; SEX FACTORS;

EID: 84901229099     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-13-NT-092     Document Type: Article

References (15)

1. Iohom, G., Ni Chonghaile, M., O'Brien, J. K., Cunningham, A. J., Fitzgerald, D. F. and Shields, D. C.: An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia. Eur. J. Anaesthesiol., 24: 912-929 (2007).
2. Schnider, T. W., Minto, C. F., Gambus, P. L., Andresen, C., Goodale, D. B., Shafer, S. L. and Youngs, E. J.: The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology, 88: 1170-1182 (1998).
3. Loryan, I., Lindqvist, M., Johansson, I., Hiratsuka, M., van der Heiden, I., van Schaik, R. H., Jakobsson, J. and Ingelman-Sundberg, M.: Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia. Eur. J. Clin. Pharmacol., 68: 397-406 (2012).
4. Girard, H., Court, M. H., Bernard, O., Fortier, L. C., Villeneuve, L., Hao, Q., Greenblatt, D. J., von Moltke, L. L., Perussed, L., et al.: Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics, 14: 501-515 (2004).
5. Court, M. H., Duan, S. X., Hesse, L. M., Venkatakrishnan, K. and Greenblatt, D. J.: Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology, 94: 110-119 (2001).
6. Zanger, U. M., Klein, K., Saussele, T., Blievernicht, J., Hofmann, M. H. and Schwab, M.: Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics, 8: 743-759 (2007).
7. Zanger, U. M. and Klein, K.: Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front. Genet., 4: 24 (2013).
8. Kansaku, F., Kumai, T., Sasaki, K., Yokozuka, M., Shimizu, M., Tateda, T., Murayama, N., Kobayashi, S. and Yamazaki, H.: Individual differences in pharmacokinetics and pharmacodynamics of anesthetic agent propofol with regard to CYP2B6 and UGT1A9 genotype and patient age. Drug Metab. Pharmacokinet., 26: 532-537 (2011).
9. Choong, E., Loryan, I., Lindqvist, M., Nordling, A., El Bouazzaoui, S., van Schaik, R. H., Johansson, I., Jakobsson, J. and Ingelman-Sundberg, M.: Sex difference in formation of propofol metabolites: A replication study. Basic Clin. Pharmacol. Toxicol., 113: 126-131 (2013).
10. Lang, T., Klein, K., Fischer, J., Nüssler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M. and Zanger, U. M.: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics, 11: 399-415 (2001).
11. Desta, Z., Saussele, T., Ward, B., Blievernicht, J., Li, L., Klein, K., Flockhart, D. A. and Zanger, U. M.: Impact of CYP2B6 polymorphism on heaptic efavirenz metabolism in vitro. Pharmacogenomics, 8: 547-558 (2007).
12. Hofmann, M. H., Blievernicht, J. K., Klein, K., Saussele, T., Schaeffeler, E., Schwab, M. and Zanger, U. M.: Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in the liver. J. Pharmacol. Exp. Ther., 325: 284-292 (2008).
13. Favetta, P., Degoute, C.-S., Perdrix, J.-P., Dufresne, C., Boulieu, R. and Guitton, J.: Propofol metabolites in man following propofol induction and maintenance. Br. J. Anaesth., 88: 653-658 (2002).
14. Girard, H., Villeneuve, L., Court, M. H., Fortier, L.-C., Caron, P., Hao, Q., von Moltke, L. L., Greenblatt, D. J. and Guillemette, C.: The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10- hydroxycamptothecin glucuronidation levels in the liver. Drug Metab. Dispos., 34: 1220-1228 (2006).
15. Takahashi, H., Maruo, Y., Mori, A., Iwai, M., Sato, H. and Takeuchi, Y.: Effect of D256N and Y483D on propofol glucuronidation by human uridine 5′-diphosphate glucuronosyltransferase (UGT1A9). Basic Clin. Pharmacol. Toxicol., 103: 131-136 (2008).